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Abstract
Background: Telomerase is a ribonucleoprotein enzyme that synthesises telomeres after cell
division and maintains chromosomal stability leading to cellular immortalisation. hTERT (human
telomerase reverse transcriptase) is the rate-limiting determinant of telomerase reactivation.
Telomerase has been associated with negative prognostic indicators in some studies. The present
study aims to detect any correlation between hTERT and the negative prognostic indicators VEGF
and PCNA by quantitatively measuring the mRNA expression of these genes in human breast
cancer and in adjacent non-cancerous tissue (ANCT).
Materials and methods: RNA was extracted from 38 breast carcinomas and 40 ANCT. hTERT
and VEGF165, VEGF189 and PCNA mRNA expressions were estimated by reverse transcriptase-
PCR (RT-PCR) and Taqman methodology.
Results: The level of expression of VEGF-165 and PCNA was significantly higher in carcinoma
tissue than ANCT (p = 0.02). The ratio of VEGF165/189 expression was significantly higher in
breast carcinoma than ANCT (p = 0.025). hTERT mRNA expression correlated with VEGF-189
mRNA (p = 0.008) and VEGF165 (p = 0.07).
Conclusions: hTERT mRNA expression is associated with the expression of the VEGF189 and
165 isoforms. This could explain the poorer prognosis reported in breast tumours expressing high
levels of hTERT. The relative expression of the VEGF isoforms is significantly different in breast
tumour to ANCT, and this may be important in breast carcinogenesis.
Introduction
Telomerase is an RNA dependant DNA polymerase, the
function of which is to synthesise the repetitive nucleotide
sequence (TTAGGG in humans) forming the telomeres at
the end of chromosomes 1. During cell division, DNA
polymerase is unable to fully replicate the ends of linear
DNA and therefore genetic material is lost from chromo-
somal ends. Telomeres form caps on the chromosomes
that prevent fusion of chromosomal ends and are dispen-
sable without compromising gene expression. Without
telomerase activity, each round of nuclear division results
in shortening of the telomeres and reaching a critical
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ase activity however appears to stabilise telomeres and
thus leads to cellular immortality [1-3]. Telomerase is
active in 80–90% of malignant tissues and many immor-
tal cell lines but not most normal somatic cells [4]. Of the
telomerase subunits, the reverse transcriptase (hTERT) is
the determinant of enzyme activity [5-7]. We have
recently demonstrated a significant correlation between
telomerase activity and hTERT mRNA expression in
human breast cancer [8]. Investigators have shown high
levels of hTERT expression to be linked to a worse progno-
sis in Wilm's tumour [9], acute myelogenous leukaemia
[10] and non-small cell lung carcinoma [11]. In breast car-
cinoma, high hTERT expression detected by quantitative
RT-PCR was found to have a statistically significant corre-
lation with disease relapse [12]. We have shown that
hTERT mRNA is over-expressed in the majority of the
breast carcinomas that we have studied [13]. The level of
expression was much higher in breast cancer specimens
than in ANCT and fibroadenomas [14]. However, apart
from a weak correlation between hTERT levels and
tumour size and progesterone receptor negativity, we have
not detected any correlation with the standard prognostic
indicators for breast carcinoma [14]. These findings could
be explained if hTERT expression were linked to a negative
prognostic indicator not routinely assessed by histopatho-
logical examination.
Angiogenesis in carcinomas, including breast carcinoma
is an important development in maintaining tumour
growth and promoting metastasis [15]. Vascular endothe-
lial growth factor (VEGF) is a cytokine that stimulates the
proliferation and migration of vascular endothelial cells,
key steps in angiogenesis [16]. A number of structurally
related peptides have now been discovered, named VEGF-
B, VEGF-C, VEGF-D and PIGF, with VEGF now being
renamed VEGF-A .15. VEGF-A is expressed in a wide range
of malignancies including breast carcinoma [17]. The
level of VEGF mRNA has been found to be higher in breast
tumour cells than in normal breast tissue [18] and higher
levels of VEGF protein are associated with increased
microvascular density and disease relapse [19,20]. The
VEGF-A gene is made up of 8 exons [21] and differential
splicing results in at least six isoforms named VEGF-121, -
145, -165, -183, -189, and -206 according to the number
of amino acids [22].
Proliferating cell nuclear antigen (PCNA) is a protein that
localises to the nucleus and is involved in DNA synthesis
and replication [23]. PCNA levels increase in cells under-
going proliferation and increased PCNA expression has
been identified as an independent prognostic indicator in
breast carcinoma [24].
The aim of this study was to quantitatively measure the
expression of hTERT, VEGF and PCNA mRNAs in human
breast cancer and in adjacent non-cancerous tissue
(ANCT) 1 cm away from the tumour in order to detect any
correlation of these negative prognostic indicators with
hTERT.
Materials and Methods
Samples
Brent Medical Ethics Committee provided ethical
approval for the use of tissue specimens for RNA extrac-
tion and analysis. Following patient consent, samples of
tissue from breast tumour and macroscopically normal
tissue 1 cm away from the tumour were taken from 40
women undergoing surgery for breast cancer. Tissue was
frozen in liquid nitrogen within 30 minutes of removal
and was then stored at -70° Celsius until use.
RNA Extraction
Total cellular RNA was extracted from specimens of breast
tissue carcinomas and matched adjacent non-cancerous
tissue using the RNeasy Mini isolation kit (Qiagen,
Hilden, Germany) according to the manufacturer's proto-
col. For cancerous tissue between 10 and 20 mg of tissue
was used. However, because ANCT tended to have a high
fat content, difficulty was experienced in obtaining suffi-
cient RNA concentration for analysis. Therefore, for ANCT
the extraction technique was modified as described by
Vidal et al [25] to include higher amounts of lysis buffer
and repeated lysis steps, and using between 100 and 200
mg of tissue. At the time of separation of tissue for RNA
extraction, a frozen section was taken from the tissue
immediately adjacent to allow confirmation of histologi-
cal features. Extraction of RNA was carried out in a labora-
tory separate to the one used for RT-PCR. Quantification
of the RNA following treatment with DNase (Promega)
was carried out in triplicate using the RiboGreen reagent
(Molecular Probes Europe BV) according to the manufac-
turer's protocol.
RT-PCR
TaqMan RT-PCR was performed in duplicate for each
sample using the ABI PRISM 7700 Sequence Detector
(Perkin-Elmer Applied Biosystems) and the TaqMan EZ
RT-PCR Core Reagents Kit (Perkin-Elmer Applied Biosys-
tems). The RT-PCR mix was set up in an extraction hood
in a laboratory distant from the one in which RNA extrac-
tion was carried out. The RT-PCR was performed using the
forward and reverse oligonucleotide primers and TaqMan
probes given in Table 1.
These oligonucleotides were designed using Primer
Express software (PE-Applied Biosystems, Warrington,
UK) and gene sequences obtained from the GenBank
database. Primers and probes were intron spanning toPage 2 of 9
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ers and probes are in exons 3 and 4 of the hTERT gene
(accession number AF128893.1) and define a 73 base pair
amplicon. The PCNA primers and probe define a 117 base
pair amplicon in the fourth and fifth exons of the gene
(accession number XM_056035). The isoforms of VEGF
that were measured were VEGF-189 and VEGF-165. In the
case of VEGF-189, the primers and probe bridge exons 4,
5 and 6 of the VEGF gene (accession number
XM_166457) to amplify a 77 base pair amplicon. For the
VEGF-165 isoform exons 4,5 and 7 are bridged (accession
number AF486837.1) and the amplicon is 73 base pairs
long.
Conditions for the reverse transcription step were 50°C
for 2 minutes, 60°C for 10 minutes, and 92°C for 5 min-
utes. The polymerase chain reaction was carried out for 50
cycles of 20 seconds at 92°C and 25 seconds at 62°C. For
the negative control RNase free water was used in the RT-
PCR mix instead of RNA. The positive control was the
amplicon created for the standard curve. The standard
curves for each mRNA were constructed using serial dilu-
tions of a single stranded sense oligonucleotide specifying
the amplicon as previously described by Bustin et al .26
and this together with the known RNA concentration was
used to quantify the mRNA copy number per microgram
of RNA for each gene. An example of a standard curve
(that for hTERT) is shown in Figure 1.
Table 1: Sequences of TaqMan Primers and Probes for RT-PCR
Gene Forward Reverse Probe
hTERT 5'GAC AGT TGC AAA GCA TTG GA3' 5'ACC TCT GCT TCC GAC AGC TC3' 5'AGC TGC ACC CTC TTC AAG TGC TGT CTG A3'
VEGF-165 5'TGT GAA TGC AGA CCA AAG AAA GA3' 5'GCT TTC TCC GCT CTG AGC AA 5'AGA GCA AGA CAA GAC AAG AAA ATC CCT GTG GGC3'
VEGF-189 5'TGT GAA TGC AGA CCA AAG AAA GA3' 5'CGT TTT TGC CCC TTT CCC3' 5'AGA GCA AGA CAA GAA AAA AAA TCA GTT GGA A3'
PCNA 5'TTA AAT TGT CAC AGA CAA GTA ATG TCG3' 5'TGG CTT TTG TAA AGA AGT TCA GGT AC3' 5'TGG TTC ATT CAT CTC TAT GGT AAC AGC TTG CTC CT3'
Standard curve for hTERT(Ct value = threshold cycle of RT-PCR at which fluorescence detectable)Figure 1
Standard curve for hTERT(Ct value = threshold cycle of RT-PCR at which fluorescence detectable)
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and 38 from tumour) were analysed using primers and
probe for the VEGF-189 isoform, in 70 of these specimens
hTERT mRNA levels were quantified. The VEGF-165 iso-
form was quantified in 39 of the specimens that had been
analysed for VEGF-189, of which 37 had undergone
hTERT mRNA measurement. Quantitative RT-PCR was
carried out for PCNA mRNA in 78 breast specimens (40
ANCT, 38 tumour) that had had hTERT mRNA measured.
Statistical analysis was carried out using WinStat for Excel
(R. Fitch Software, Staufen, Germany) and Stata 5.0 (Stata
Corp, College Station, Texas).
Results and Statistical Analysis
All specimens had detectable mRNA for PCNA and both
isoforms of VEGF. For PCNA expression ranged from 2.62
× 105 to 1.43 × 107 (mean 2.59 × 106) in ANCT and from
4.65 × 105 to 4.2 × 107 (mean 7.65 × 106) in tumour
tissue. The ratio of PCNA mRNA expression in tumour to
adjacent tissue ranged from 0.09 to 22.93 (mean 4.97)
and PCNA was present in greater amounts in 25 out of 31
(80%) matched tissue specimens. Using the paired t test,
the increased expression of PCNA in tumours compared
to adjacent tissue was statistically significant (p = 0.02).
In 16 (51%) specimens, PCNA was higher by more than a
factor of 2, in 12 (39%) by more than a factor of 3 and in
7 (23%) by more than a factor of 10. We were unable to
detect any relationship between over-expression of hTERT
in tumours (ratio of mRNA in tumour to ANCT > 1 × 104)
and PCNA over-expression (ratio of mRNA in tumour to
ANCT >2 or >3) using the χ2 test (p > 0.1). Using the prod-
uct moment correlation coefficient on the log-trans-
formed data no significant relationship was found
between PCNA and hTERT mRNA levels in tumour (Fig-
ure 2) (correlationcoefficient-0.324, p = 0.3), or in adja-
cent non-cancerous tissue (correlation coefficient -0.199,
p = 0.1).
Shows no significant relationship between PCNA and hTERT mRNA levels in tumour samplesFigure 2
Shows no significant relationship between PCNA and hTERT mRNA levels in tumour samples.
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and 2.9 × 107 (mean 4.55 × 106) in ANCT and between
2.02 × 101 and 6.63 × 107 (mean 8.85 × 106) in tumour tis-
sue. In the matched specimens, (n = 31) the VEGF-189
expression in tumour compared to ANCT was higher in 16
(52%) by a factor of between 1.5 and 63 although this was
not significantly different using the paired t test (p = 0.12).
We used the product moment correlation coefficient on
the log-transformed data and found a significant positive
correlation between hTERT and VEGF-189 mRNA levels
in tumour tissue (coefficient 0.423, p = 0.008) but not in
ANCT (Figure 3).
The expression of VEGF-165 mRNA in ANCT was between
1.68 × 107 and 2.60 × 108 copy numbers per µg of RNA
(mean 7.2 × 107) and in tumour was between 7.7 × 105
and 1.67 × 109 (mean 3.57 × 108). The expression of
VEGF-165 was significantly higher in tumour tissue than
in adjacent tissue using the paired t test (p = 0.02). There
was a significant correlation between the level of 165 iso-
form and the 189 isoform both in ANCT (coefficient 0.67,
p = 0.001) and in tumour tissue (coefficient 0.83, p = 1.98
× 10-6) (Figure 4). The expression of VEGF165 mRNA pos-
itively correlated with that of hTERT in tumours but this
just failed to reach statistical significance (coefficient 0.33,
p = 0.07) (Figure 5). There was no correlation in ANCT
(coefficient 0.02, p = 0.46). In fifteen specimens where
There is a significant positive correlation between hTERT and VEGF-189 mRNA levels in tumour tissue (coefficient 0.423, p = 0.008)Figure 3
There is a significant positive correlation between hTERT and VEGF-189 mRNA levels in tumour tissue (coefficient 0.423, p = 
0.008).
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Journal of Carcinogenesis 2004, 3 http://www.carcinogenesis.com/content/3/1/1both isoforms of VEGF were analysed in both cancerous
and adjacent tissue, the ratio of VEGF165 to 189 mRNA
expressions was examined. The ratio of isoform 165/189
expressions ranged between 4.00 and 46.59 (mean 15) in
ANCT and between 7.44 and 38,421 (mean 3002) in can-
cerous tissue. In 80% (n = 12), the ratio of 165/189 iso-
form expressions was higher in tumours than in the
adjacent tissue by a factor of between 1.3 and 9596 (mean
738). As the results were highly skewed, these data were
log transformed before analysis with the paired t test and
this showed a significant difference between the ratio of
165/189 isoform expression in tumours and adjacent tis-
sue (p = 0.025).
Discussion
We found no statistically significant relationship between
PCNA and hTERT over-expression in breast tumour tissue,
or between absolute levels of these two mRNAs in tumour
or adjacent non-cancerous tissue. To our knowledge, only
one previous study has investigated hTERT and PCNA
expression in malignancy, that of Nakanishi et al who also
found no relationship between the two in urothelial
cancers using in situ hybridisation and immunohisto-
chemistry[27]. The correlation between PCNA and telom-
erase activity has been investigated in gastric carcinoma
[28] and cervical intraepithelial neoplasia [29], and again
no relationship found. These findings suggest that the
association between hTERT expression and worsened
prognosis that has been reported is not due to increased
PCNA expression.
We have however found a significant correlation between
the VEGF-189 isoform and hTERT mRNA expressions (p =
0.008) and a trend towards significant correlation
between VEGF165 and hTERT mRNA expressions (p =
0.07) in breast cancer tissue, suggesting a possible
pathway through which high expression of hTERT could
be linked to worsened disease prognosis. Since VEGF
expression is known to increase the likelihood of tumour
metastasis .17, it might be expected that high levels of
hTERT would therefore also be correlated with increased
lymph node positivity. Although we did not detect such
an association in our sample [14] and neither did Bieche
et al [12], such a connection has been reported with
There is a significant correlation between the level of 165 isoform and the189 isoform both in tumour tissue (coefficient 0.83, p = 1.98 × 10-6)Figure 4
There is a significant correlation between the level of 165 isoform and the189 isoform both in tumour tissue (coefficient 0.83, 
p = 1.98 × 10-6).
VEGF-165 against VEGF-189 mRNA Expression in Cancerous Tissue
1.00E+04
1.00E+05
1.00E+06
1.00E+07
1.00E+08
1.00E+09
1.00E+10
1.00E+00 1.00E+01 1.00E+02 1.00E+03 1.00E+04 1.00E+05 1.00E+06 1.00E+07 1.00E+08
VEGF-189 mRNA in tumour tissue
VE
G
F-
16
5 
m
RN
A 
in
 tu
m
ou
r t
is
su
ePage 6 of 9
(page number not for citation purposes)
Journal of Carcinogenesis 2004, 3 http://www.carcinogenesis.com/content/3/1/1telomerase and nodal status in breast cancer [30,31]. It
may be that any relationship that does exist is masked in
studies measuring mRNA by the presence of splice vari-
ants with different physiological activity, however it is sur-
prising therefore that the correlation between VEGF-189
and hTERT mRNA is still apparent. The activities of the
splice variants of VEGF-A, like those of hTERT, are cur-
rently poorly understood. The 121,165 and 189 isoforms
are all reported to be present in breast tumour tissue with
the VEGF165 isoform being the most important ang-
iogenic factor [32,33]. The 165 variant has been found to
be an independent negative prognostic indicator in breast
cancer patients [32-35]. The VEGF189 isoform has been
shown to be more strongly bound to the cell membrane
than other isoforms and therefore has a high potential in
local angigenesis and tumour growth in the cancer induc-
tive microenvironment [36]. Furthermore, the VEGF189
mRNA has been reported to show a greater correlation
with tumour angiogenesis and clinical outcome than
other isoforms (121,165 and 206) in some epithelial can-
cers [37].
We have found both the overall expression of the 165 iso-
form and the ratio of VEGF-165 to 189 mRNA to be sig-
nificantly increased in tumour tissue compared to
adjacent tissue. This suggests that the 165 isoform may be
important in breast carcinogenesis, although previously it
has been reported that the proportions of each of the
VEGF-A isoforms remains the same in breast carcinoma
tissue as in benign tissue [15].
We have also detected high levels of both isoforms of
VEGF in adjacent non-cancerous tissue in our study. This
is in keeping with other studies where VEGF 189,121 and
165 isoforms have been found in normal tissues .38 and
increased levels of VEGF have been reported in benign
The expression of VEGF165 mRNA positively correlated with that of hTERT in tumours but this just failed to reach statistical significance (coefficient 0.33, p = 0.07)Figure 5
The expression of VEGF165 mRNA positively correlated with that of hTERT in tumours but this just failed to reach statistical 
significance (coefficient 0.33, p = 0.07).
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Journal of Carcinogenesis 2004, 3 http://www.carcinogenesis.com/content/3/1/1breast tissue from pre-menopausal women compared to
post-menopausal women, suggesting hormonal regula-
tion [15].
Further work in this area is required to corroborate this
apparent relationship between VEGF-189 and hTERT, ide-
ally using primers designed to amplify only the functional
variants of hTERT mRNA. In addition, studies aimed at
illustrating the physiological significance of the VEGF iso-
forms will be invaluable in clarifying the relevance of
altered isoform ratios between benign and malignant
tissues.
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